EP0513058A1 - Verwendung von bekannte uracile zur herstellung von arzneimittel für die verhütungen und behandlung von krankheitszusännden, die auf proliferativen prozessen beruhen. - Google Patents
Verwendung von bekannte uracile zur herstellung von arzneimittel für die verhütungen und behandlung von krankheitszusännden, die auf proliferativen prozessen beruhen.Info
- Publication number
- EP0513058A1 EP0513058A1 EP91902708A EP91902708A EP0513058A1 EP 0513058 A1 EP0513058 A1 EP 0513058A1 EP 91902708 A EP91902708 A EP 91902708A EP 91902708 A EP91902708 A EP 91902708A EP 0513058 A1 EP0513058 A1 EP 0513058A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- treatment
- compounds
- formula
- hydrogen
- proliferative processes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Definitions
- the invention relates to the use of known uracil for the production of new drugs.
- DE-OS 1942405 discloses piperazinylalkylaminouracils with blood pressure-sending properties.
- the invention therefore relates to the use of compounds of the formula I.
- Rl is hydrogen or 1-6C-alkyl
- R2 is hydrogen or 1-6C-alkyl
- R3 is hydrogen or 1-6C-alkyl
- R4 is hydrogen, one or two 1-4C-alkyl radicals, one or two 1-4C-alkoxy radicals or one or two halogen atoms and A 2-4C-alkylene, and their pharmacologically acceptable salts for the preparation of medicaments for the prevention and Treatment of disease states that are based on proliferative processes, especially in vessels.
- 1-6C-A1kyl stands for straight-chain or branched alkyl radicals with 1 to 6 carbon atoms.
- hexyl, pentyl, neopentyl, isopentyl, butyl, i-butyl, sec-butyl, tert-butyl, propyl, isopropyl or in particular the ethyl or methyl radical may be mentioned .
- 1-4C-alkyl radicals are the butyl, i-butyl, sec-butyl, tert-butyl, propyl, isopropyl or in particular the ethyl or methyl radical.
- 1-4C-alkoxy radicals contain one of the 1-4C-alkyl radicals mentioned above.
- the methoxy and ethoxy radicals are preferred.
- Halogen atoms are bromine and especially fluorine and chlorine.
- C-alkylene which can be straight-chain or branched, is for example.
- tetramethylene 1,2-dimethylethylene, 1,1-dimethylethylene, 2,2-dimethyl ethylene, isopropylidene, 1-methylethylene, ethylene and especially propylene.
- Suitable as such are, for example, water-soluble and water-insoluble acid addition salts, such as the hydrochloride, hydrobride, hydroiodide, phosphate, nitrate, sulfate, acetate, citrate, gluconate, benzoate, hibenzate, fendizoate, butyrate, sulfosalicylate, maleate, laurate , Malate, fumarate, succinate, oxalate, tartrate, sonata, metembonate, stearate, tosilate, 2-hydroxy-3-naphthoate, 3-hydroxy-2-naphthoate or mesilate.
- water-soluble and water-insoluble acid addition salts such as the hydrochloride, hydrobride, hydroiodide, phosphate, nitrate, sulfate, acetate, citrate, gluconate, benzoate, hibenzate, fendizoate, butyrate, sulfosal
- arteriosclerosis diseases which are based on proliferative processes in vessels are primarily all forms of arteriosclerosis, such as, for example, central arteriosclerosis, coronary arteriosclerosis, arteriosclerosis of the brain vessels, arteriosclerosis of the kidneys, arteriosclerosis of the mesentery or that Arteriosclerosis of the extremity vessels.
- the compounds of the formula I can be used, for example, to prevent and treat the following diseases and pathological changes: Restenosis after percutaneous translucent angioplasty or coronary bypass surgery, angina pectoris, myocardial infarction, cerebral haemorrhage and softening, vascular shrinking kidney, angina abdominalis, intermittent claudication, etc.
- the invention therefore furthermore relates to a method for the treatment of mammals, in particular humans, who are suffering from a disease based on proliferative processes in vessels.
- the method is characterized in that the diseased individual is administered a therapeutically effective and pharmacologically tolerable amount of one or more compounds of the formula I and / or their pharmacologically tolerable salts.
- the invention relates to the use of compounds of formula I and their salts for the treatment of mammals, in particular humans, who are suffering from ei ⁇ ner 'on prol Ferati en processes in vessels based disease.
- the pharmacologically active compounds of the formula I and their salts are used either as such or, preferably, in combination with suitable pharmaceutical auxiliaries in the form of tablets, coated tablets , Capsules, suppositories, plasters (for transdermal drug application), emulsions, suspensions, aerosols, sprays, ointments, creams, gels or solutions, the active ingredient content advantageously being between 0.1 and 95%.
- auxiliaries which are suitable for the desired pharmaceutical formulations on the basis of his specialist knowledge.
- active substance carriers for example antioxidants, dispersants, emulsifiers, defoamers, flavoring agents, preservatives, solubilizers, dyes or in particular permeation promoters and complexing agents (e.g. cyclodextrins) can be used.
- the active substances can be administered rectally, parenterally (perlingually, intravenously, percutaneously) or orally.
- the pharmaceutical preparations can also contain one or more other pharmacologically active constituents of other groups of medicaments.
- a preferred embodiment of the invention is the use of compounds of the formula I in which R1 is methyl, R2 is methyl, R3 is hydrogen or methyl, R4 is hydrogen, methyl, methoxy or chlorine and A is propylene, and their pharmaceutically acceptable salts for the preparation of drugs for the prevention and treatment of the disease states mentioned.
- a particularly preferred embodiment of the invention is the use of 6 - ⁇ [3- [4- (2-methoxyphenyl) -1-piperazinyl] propyl] amino ⁇ -1,3-dimethyluraci1 and of 6 - ⁇ [3- [4- (2-methoxyphenyl) -1-piperazinyl] propyl] amino ⁇ -1,3,5-trimethylura ⁇ ci1 and its pharmacologically acceptable salts for the production of medicaments for the prevention and treatment of the disease states mentioned.
- the compounds of the formula I and their salts are outstandingly suitable for the prevention and treatment of disease states which are based on proliferative processes.
- the blood pressure-sending action of compounds of the formula I and their salts is known. Since arteriosclerosis is often associated with hypertension, the use of compounds of the formula I and their salts is of particular importance in hypertensives with accompanying arteriosclerosis.
- test substances were administered orally once a day starting with 2 days before the lesion up to 14 days afterwards (2.5 ml / kg).
- the substances were suspended in 4% solution of Methocel E15.
- the carotids were removed at the end of the tests.
- the amount of DNA after sample preparation was determined fluorometrically from defined 5 mm long pieces of vessel from the central area of the lesion, and on the other hand the neointima or media areas of haematoxylin-eosin stained by measuring with an electronic stylus.
- test results determined in the test model described are summarized in Table 1 below. The following numbers were assigned to the test substances:
- compound 1 achieved an inhibition of 27 or 37% with regard to new DNA or intima, in the high dose 46% inhibition.
- the latter effect corresponds to that which can be achieved in the same model by continuous infusion of heparin (A.W. Clowes and M.M. Clowes, Laboratory Investigation 52, 611-616, 1985).
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- General Chemical & Material Sciences (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CH321/90 | 1990-02-01 | ||
CH32190 | 1990-02-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
EP0513058A1 true EP0513058A1 (de) | 1992-11-19 |
Family
ID=4184357
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP91902708A Withdrawn EP0513058A1 (de) | 1990-02-01 | 1991-01-29 | Verwendung von bekannte uracile zur herstellung von arzneimittel für die verhütungen und behandlung von krankheitszusännden, die auf proliferativen prozessen beruhen. |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP0513058A1 (de) |
JP (1) | JPH05504136A (de) |
AU (1) | AU7078691A (de) |
WO (1) | WO1991011185A1 (de) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19607487C2 (de) * | 1996-02-28 | 1998-09-10 | Byk Gulden Lomberg Chem Fab | Verwendung von alpha1-Adrenoceptor-Antagonisten |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE755015A (fr) | 1969-08-20 | 1971-02-01 | Byk Gulden Lomberg Chem Fab | Piperazinyl-alcoylamino-uraciles substitues par un groupe aryle, leurs ethers et thioethers, ainsi que leur procede de preparation |
-
1991
- 1991-01-29 AU AU70786/91A patent/AU7078691A/en not_active Abandoned
- 1991-01-29 JP JP3503089A patent/JPH05504136A/ja active Pending
- 1991-01-29 EP EP91902708A patent/EP0513058A1/de not_active Withdrawn
- 1991-01-29 WO PCT/EP1991/000159 patent/WO1991011185A1/de not_active Application Discontinuation
Non-Patent Citations (1)
Title |
---|
See references of WO9111185A1 * |
Also Published As
Publication number | Publication date |
---|---|
WO1991011185A1 (de) | 1991-08-08 |
JPH05504136A (ja) | 1993-07-01 |
AU7078691A (en) | 1991-08-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE602004010531T2 (de) | Verwendung von fumarsäure-derivaten zur behandlung von herzinsuffizienz und asthma | |
EP0152944A2 (de) | Verwendung von Adenosin-Derivaten als Antiallergica und Arzneimittel, die diese enthalten | |
CH649921A5 (de) | Festes cerebralwirksames mittel. | |
DE3319347C2 (de) | ||
EP0038438B1 (de) | Substituierte 1,2,5-Oxadiazol-2-oxide zur Anwendung als Arzneimittel und sie enthaltende Arzneimittel | |
DE60210428T2 (de) | Stickstoffoxid(NO)-freisetzende Metallkomplexe | |
EP0513058A1 (de) | Verwendung von bekannte uracile zur herstellung von arzneimittel für die verhütungen und behandlung von krankheitszusännden, die auf proliferativen prozessen beruhen. | |
DE3116029C2 (de) | ||
DE2609746A1 (de) | Piperazinverbindungen sowie arzneimittel, die diese verbindungen enthalten | |
EP0207193A2 (de) | Synergistische Kombination von Flupirtin und 4-Acetamido-phenol | |
EP0005732B1 (de) | Verwendung von 2-Amino-oxazolo- oder 2-Amino-thiazolo-[5,4-d]azepinen sowie deren Säureadditionssalzen zur Herstellung eines Arzneimittels für die Verwendung bei der Bekämpfung von Angina Pectoris | |
DE3500756A1 (de) | Verwendung von chinolonen zur behandlung der herzinsuffizienz | |
WO1992008457A1 (de) | Verwendung von thiazoloisoindolinon-derivaten als antivirale arzneimittel | |
WO1986000892A1 (en) | New compounds having an immunizing activity | |
DE2029510C3 (de) | Dibenzofuranderivate und deren pharmazeutisch verträgliche Säureadditionssalze sowie Verfahren zu deren Herstellung und Arzneimittel mit einem Gehalt dieser Verbindungen | |
DE2609147A1 (de) | Propionsaeuresalze basischer aminosaeuren | |
DE2401446A1 (de) | Pharmazeutische zubereitungen zur linderung von hautproliferationserkrankungen | |
DE2716374C2 (de) | N-2-(p-Chlorphenoxy)-isobutyryl-N'-morpholinmethylharnstoff, dessen Salze, Verfahren zu deren Herstellung und pharmazeutische Zubereitung | |
DE1792811C2 (de) | "Arzneimittel mit koronargefäßerweiternder Wirkung" | |
EP0276369B1 (de) | Verwendung von Anipamil als Artereosklerosemittel | |
DE69532963T2 (de) | Verwendung von 4-acylaminopyridin derivaten zur Herstellung eines Medikaments für die Behandlung von zerebrovaskulären Erkrankungen | |
DE2544100A1 (de) | Arzneimittel mit einem gehalt an 2-naphthyl-buttersaeurederivaten | |
DE69630561T2 (de) | Verwendung von 4-Amino-6-hydroxypyrazolo[3,4-d]pyrimidin zur Herstellung eines blutdrucksenkenden Mittels | |
DE2901629A1 (de) | 4-pyrimidylsulfide, verfahren zu ihrer herstellung, sie enthaltende arzneimittel und verwendung | |
DE1915795C3 (de) | N- (3,4,5-Trimethoxycinnamoyl) -N'- (carbonylmethyl) -piperazinderivate und ihre Säureadditionssalze, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19920722 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE |
|
17Q | First examination report despatched |
Effective date: 19960401 |
|
GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 19990105 |